BRPI0517790A - métodos e composições fluoradas para tratar doenças relacionadas à amilóide - Google Patents

métodos e composições fluoradas para tratar doenças relacionadas à amilóide

Info

Publication number
BRPI0517790A
BRPI0517790A BRPI0517790-1A BRPI0517790A BRPI0517790A BR PI0517790 A BRPI0517790 A BR PI0517790A BR PI0517790 A BRPI0517790 A BR PI0517790A BR PI0517790 A BRPI0517790 A BR PI0517790A
Authority
BR
Brazil
Prior art keywords
methods
compositions
fluorinated
related diseases
treating
Prior art date
Application number
BRPI0517790-1A
Other languages
English (en)
Inventor
Xiangi Kong
Xinfu Wu
Abderrahim Bouzide
Isabelle Valade
David Migneault
Francesco Bellini
Original Assignee
Neurochem Int Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurochem Int Ltd filed Critical Neurochem Int Ltd
Publication of BRPI0517790A publication Critical patent/BRPI0517790A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C229/06—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton
    • C07C229/08—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to hydrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C229/20—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated the carbon skeleton being further substituted by halogen atoms or by nitro or nitroso groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
    • C07C309/03—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C309/13—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing nitrogen atoms, not being part of nitro or nitroso groups, bound to the carbon skeleton
    • C07C309/14—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing nitrogen atoms, not being part of nitro or nitroso groups, bound to the carbon skeleton containing amino groups bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
    • C07C309/03—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C309/13—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing nitrogen atoms, not being part of nitro or nitroso groups, bound to the carbon skeleton
    • C07C309/14—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing nitrogen atoms, not being part of nitro or nitroso groups, bound to the carbon skeleton containing amino groups bound to the carbon skeleton
    • C07C309/15—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing nitrogen atoms, not being part of nitro or nitroso groups, bound to the carbon skeleton containing amino groups bound to the carbon skeleton the nitrogen atom of at least one of the amino groups being part of any of the groups, X being a hetero atom, Y being any atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
    • C07C309/19—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of a saturated carbon skeleton containing rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
    • C07C309/24—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of a carbon skeleton containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C313/00—Sulfinic acids; Sulfenic acids; Halides, esters or anhydrides thereof; Amides of sulfinic or sulfenic acids, i.e. compounds having singly-bound oxygen atoms of sulfinic or sulfenic groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C313/02—Sulfinic acids; Derivatives thereof
    • C07C313/04—Sulfinic acids; Esters thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/23—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C323/24—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/25—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/18—Systems containing only non-condensed rings with a ring being at least seven-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/10—One of the condensed rings being a six-membered aromatic ring the other ring being six-membered, e.g. tetraline
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2603/00—Systems containing at least three condensed rings
    • C07C2603/56—Ring systems containing bridged rings
    • C07C2603/58—Ring systems containing bridged rings containing three rings
    • C07C2603/70—Ring systems containing bridged rings containing three rings containing only six-membered rings
    • C07C2603/74—Adamantanes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurology (AREA)
  • Public Health (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

MéTODOS E COMPOSIçõES FLUORADAS PARA TRATAR DOENçAS RELACIONADAS A AMILóIDE. Métodos, compostos, composições farmacêuticas e estojos são descritos para tratar ou prevenir doença relacionada a amilóide. Também descritos estão métodos, compostos, composições farmacêuticas e estojos para detector, diagnosticar, monitorar e tratar ou prevenir doença relacionada a amilóide.
BRPI0517790-1A 2004-11-12 2005-11-14 métodos e composições fluoradas para tratar doenças relacionadas à amilóide BRPI0517790A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US62776504P 2004-11-12 2004-11-12
US63896504P 2004-12-22 2004-12-22
PCT/IB2005/004152 WO2006059252A2 (en) 2004-11-12 2005-11-14 Methods and fluorinated compositions for treating amyloid-related diseases

Publications (1)

Publication Number Publication Date
BRPI0517790A true BRPI0517790A (pt) 2008-10-21

Family

ID=36463402

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0517790-1A BRPI0517790A (pt) 2004-11-12 2005-11-14 métodos e composições fluoradas para tratar doenças relacionadas à amilóide

Country Status (9)

Country Link
US (1) US20060183800A1 (pt)
EP (1) EP1828111A2 (pt)
JP (1) JP2008519822A (pt)
AU (1) AU2005310986A1 (pt)
BR (1) BRPI0517790A (pt)
CA (1) CA2586111A1 (pt)
IL (1) IL183079A0 (pt)
MX (1) MX2007005507A (pt)
WO (1) WO2006059252A2 (pt)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040208875A1 (en) * 1995-03-15 2004-10-21 Queen's University At Kingston Method for treating amyloidosis
AU5994900A (en) * 1999-07-09 2001-01-30 Isis Innovation Limited Compounds for inhibiting diseases and preparing cells for transplantation
US20070010573A1 (en) 2003-06-23 2007-01-11 Xianqi Kong Methods and compositions for treating amyloid-related diseases
US7244764B2 (en) * 2003-06-23 2007-07-17 Neurochem (International) Limited Methods and compositions for treating amyloid-related diseases
WO2006085149A2 (en) 2004-12-22 2006-08-17 Neurochem (International) Limited Methods and compositions for treating amyloid-related diseases
TW200716088A (en) * 2005-04-15 2007-05-01 Neurochem Int Ltd Formulations and methods for treating amyloidosis
WO2007023389A2 (en) * 2005-07-21 2007-03-01 Neurochem (International) Limited Polymorphic forms of 3-amino-1-propanesulfonic acid
EP1968561B8 (en) * 2005-12-22 2010-10-20 Kiacta Sàrl Treatment of diabetic nephropathy
DK2089417T3 (en) 2006-10-12 2015-03-23 Bhi Ltd Partnership Methods, Compounds, Compositions and Vehicles for Delivery of 3-Amion-1-Propanesulfonic Acid
CN101730529A (zh) * 2006-12-22 2010-06-09 贝鲁斯健康(国际)有限公司 用于治疗代谢疾病和糖尿病的方法、化合物和组合物
JP5650642B2 (ja) 2008-08-01 2015-01-07 バイオキシネス ファーマシューティカルズ， インコーポレイテッド メチオニンアナログおよびそれらを使用する方法
US20110165037A1 (en) * 2010-01-07 2011-07-07 Ismagilov Rustem F Interfaces that eliminate non-specific adsorption, and introduce specific interactions
US20200230218A1 (en) * 2019-01-18 2020-07-23 L & J Bio Co., Ltd. Method of treating central nervous system disease

Family Cites Families (99)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1944300A (en) * 1930-05-12 1934-01-23 Ig Farbenindustrie Ag Aliphatic amine sulphonic acid containing eight or more carbon atoms
US2531468A (en) * 1949-04-14 1950-11-28 Eastman Kodak Co Polyvinyl sulfonates and process for their preparation
US2730523A (en) * 1952-08-16 1956-01-10 Eastman Kodak Co 5-nitrothiazoleazo-n-fluoroalkyl-aniline compounds
DE1122064B (de) * 1960-01-09 1962-01-18 Basf Ag Verfahren zur Einfuehrung von alyphatischen Kohlenwasserstoffresten in organische Verbindungen, die Hydroxylgruppen, tertiaere Aminogruppen, aromatische gebundene Sulfhydrylgruppen und bzw. oder aromatisch gebundene primaere oder sekundaere Aminogruppen enthalten
US3218352A (en) * 1962-05-03 1965-11-16 Abbott Lab Homotaurine process
US3658966A (en) * 1969-09-15 1972-04-25 Kowa Co Methods of treating hypertension
US3872125A (en) * 1973-03-03 1975-03-18 Sandoz Ag 3-substituted-4-aryl isoquinolines
US4085134A (en) * 1974-02-15 1978-04-18 Petrolite Corporation Amino-phosphonic-sulfonic acids
US3920833A (en) * 1974-08-08 1975-11-18 Stanley Drug Products Inc Antifibrinolytic agents
FR2384751A1 (fr) * 1977-03-23 1978-10-20 Francaise Coop Pharma Nouveaux derives de la taurine a activite neuro-musculaire renforcee
FR2457281A1 (fr) * 1979-05-23 1980-12-19 Meram Lab Nouveaux derives de l'acide 3-aminopropanesulfonique ayant une activite membranaire renforcee
US4255448A (en) * 1979-09-10 1981-03-10 Wisconsin Alumni Research Foundation Method for reducing epileptiform activity
US4448779A (en) * 1981-07-16 1984-05-15 Sanofi Use of MS salt in geriatric medicine
JPS5879022A (ja) * 1981-11-04 1983-05-12 Bitamin Kenkyusho:Kk 第四級窒素原子を含有する新規な金属架橋高分子化合物、その製法及び該高分子化合物を有効成分とする高脂血症治療剤
US5525727A (en) * 1982-05-18 1996-06-11 University Of Florida Brain-specific drug delivery
US5087618A (en) * 1982-05-18 1992-02-11 University Of Florida Redox carriers for brain-specific drug delivery
US4540564A (en) * 1982-05-18 1985-09-10 University Of Florida Brain-specific drug delivery
FR2529546A1 (fr) * 1982-07-05 1984-01-06 Meram Lab Nouveaux sels d'amino-(et imino-)acides a, o-sulfoniques n-substitues, vecteurs cationiques de haute penetration cellulaire
US4522811A (en) * 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
DE3343530A1 (de) * 1983-12-01 1985-06-13 Max Planck Gesellschaft Arzneimittel mit verbesserter penetration der gewebsmembran
US4737353A (en) * 1984-04-13 1988-04-12 Union Carbide Corporation Beryllium-aluminum-phosphorus-silicon-oxide molecular sieve compositions
US4612185A (en) * 1984-10-15 1986-09-16 Mallinckrodt, Inc. Methods and compositions for enhancing magnetic resonance imaging
DE3438291A1 (de) * 1984-10-19 1986-04-24 Röhm GmbH, 6100 Darmstadt Verfahren zur herstellung einer waessrigen ueberzugsmitteldispersion und ihre verwendung zum ueberziehen von arzneimitteln
EP0179383B1 (en) * 1984-10-25 1991-05-29 Hoechst-Roussel Pharmaceuticals Incorporated 9-amino-1,2,3,4-tetrahydroacridin-1-ol and related compounds, a process for their preparation and their use as medicaments
US4913853A (en) * 1984-11-14 1990-04-03 Mallinckrodt, Inc. Compositions useful for fluorine magnetic resonance imaging
MX9203291A (es) * 1985-06-26 1992-08-01 Liposome Co Inc Metodo para acoplamiento de liposomas.
JPH0733332B2 (ja) * 1985-11-19 1995-04-12 富山化学工業株式会社 痴呆症状改善・治療剤
US5023252A (en) * 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
JPH0786122B2 (ja) * 1986-05-30 1995-09-20 日本ペイント株式会社 三次元架橋された微小樹脂粒子およびその製造法
US5039794A (en) * 1986-09-19 1991-08-13 Otsuka Pharmaceutical Co., Ltd. Tumor egress factor and processes for producing the same
US4847082A (en) * 1987-01-21 1989-07-11 Robert Sabin Method of treatment of Alzheimer's disease using phytic acid
US5166320A (en) * 1987-04-22 1992-11-24 University Of Connecticut Carrier system and method for the introduction of genes into mammalian cells
IT1205042B (it) * 1987-05-28 1989-03-10 Crinos Industria Farmaco Composizione farmaceutica ad attivita' terapeutica per il trattamento della demenza senile di tipo alzheimer
US4838274A (en) * 1987-09-18 1989-06-13 Air Products And Chemicals, Inc. Perfluoro-crown ethers in fluorine magnetic resonance imaging
JPH03503632A (ja) * 1987-11-18 1991-08-15 ステート　オブ　オレゴン　アクティング　バイ　アンド　スルー　ザ　ステート　ボード　オブ　ハイアー　エデュケイション　オン　ビハーフ　オブ　オレゴン　ヘルス　サイエンシズ　ユニバーシティー 血液脳関門を経る治療薬の分別送達
US5002935A (en) * 1987-12-30 1991-03-26 University Of Florida Improvements in redox systems for brain-targeted drug delivery
US5017566A (en) * 1987-12-30 1991-05-21 University Of Florida Redox systems for brain-targeted drug delivery
US5284876A (en) * 1988-02-26 1994-02-08 Neuromedica, Inc. Method of treating tardive dyskinesia using dopaminergic agents of prodrugs of therapeutic agents
US4960815A (en) * 1988-09-22 1990-10-02 Warner-Lambert Company Isotopically-labeled polycyclic amine derivatives
US5081304A (en) * 1988-09-22 1992-01-14 Warner-Lambert Company Isotopically-labeled polycyclic amine derivatives
DE3834704A1 (de) * 1988-10-07 1990-06-07 Schering Ag Fluorsubstituierte benzolderivate
US5108921A (en) * 1989-04-03 1992-04-28 Purdue Research Foundation Method for enhanced transmembrane transport of exogenous molecules
US5194654A (en) * 1989-11-22 1993-03-16 Vical, Inc. Lipid derivatives of phosphonoacids for liposomal incorporation and method of use
US5234680A (en) * 1989-07-31 1993-08-10 Johns Hopkins Univ. Perfluoro-t-butyl-containing compounds for use in fluorine-19 NMR and/or MRI
US5116599A (en) * 1989-07-31 1992-05-26 Johns Hopkins Univ. Perfluoro-t-butyl-containing compounds for use in fluorine-19 nmr and/or mri
DK437289D0 (da) * 1989-09-04 1989-09-04 Hans Bundgaard Prodrug derivatives of thyrotropin-releasing hormone (trh)
US5672683A (en) * 1989-09-07 1997-09-30 Alkermes, Inc. Transferrin neuropharmaceutical agent fusion protein
US5977307A (en) * 1989-09-07 1999-11-02 Alkermes, Inc. Transferrin receptor specific ligand-neuropharmaceutical agent fusion proteins
US5527527A (en) * 1989-09-07 1996-06-18 Alkermes, Inc. Transferrin receptor specific antibody-neuropharmaceutical agent conjugates
US5463092A (en) * 1989-11-22 1995-10-31 Vestar, Inc. Lipid derivatives of phosphonacids for liposomal incorporation and method of use
JPH03236315A (ja) * 1989-12-05 1991-10-22 Nippon Oil & Fats Co Ltd 抗精神病薬
US5236694A (en) * 1990-02-21 1993-08-17 The Board Of Regents, The University Of Texas System 19f labelled dextrans and antibodies as nmr imaging and spectroscopy agents
US5385915A (en) * 1990-05-16 1995-01-31 The Rockefeller University Treatment of amyloidosis associated with Alzheimer disease using modulators of protein phosphorylation
US5242932A (en) * 1991-12-17 1993-09-07 The Rockefeller University Treatment of amyloidosis associated with alzheimer disease
US5177064A (en) * 1990-07-13 1993-01-05 University Of Florida Targeted drug delivery via phosphonate derivatives
ES2100222T3 (es) * 1990-07-19 1997-06-16 Nippon Zoki Pharmaceutical Co Derivados del acido aminoalcansulfonico y compuestos farmaceuticos a utilizar para prevenir o tratar afecciones cardiacas.
US5070213A (en) * 1990-08-17 1991-12-03 E. I. Du Pont De Nemours And Company Perfluoro-4,4'-bis(2,2-dimethyl-1,3-dioxolane) and its preparation and use
US5827819A (en) * 1990-11-01 1998-10-27 Oregon Health Sciences University Covalent polar lipid conjugates with neurologically active compounds for targeting
JP2701090B2 (ja) * 1990-11-30 1998-01-21 和光純薬工業株式会社 被酸化性呈色試薬
US5668117A (en) * 1991-02-22 1997-09-16 Shapiro; Howard K. Methods of treating neurological diseases and etiologically related symptomology using carbonyl trapping agents in combination with previously known medicaments
US5164295A (en) * 1991-03-06 1992-11-17 The Upjohn Company Method for identifying amyloid protein-extracellular matrix protein affinity altering compounds
US5192753A (en) * 1991-04-23 1993-03-09 Mcgeer Patrick L Anti-rheumatoid arthritic drugs in the treatment of dementia
US5248498A (en) * 1991-08-19 1993-09-28 Mallinckrodt Medical, Inc. Fullerene compositions for magnetic resonance spectroscopy and imaging
US5254342A (en) * 1991-09-30 1993-10-19 University Of Southern California Compositions and methods for enhanced transepithelial and transendothelial transport or active agents
US5318770A (en) * 1991-10-25 1994-06-07 Mallinckrodt Medical, Inc. Trifluoromethyl analogs of X-ray contrast media for magnetic resonance imaging
US5362477A (en) * 1991-10-25 1994-11-08 Mallinckrodt Medical, Inc. 19F magnetic resonance imaging agents which include a nitroxide moiety
ATE147404T1 (de) * 1991-12-19 1997-01-15 Ciba Geigy Ag Aminosulfonsäurederivate und verfahren zu ihrer herstellung
US5258402A (en) * 1992-06-11 1993-11-02 Mcneil-Ppc, Inc. Imidate derivatives of pharmaceutically useful anticonvulsant sulfamates
US5276059A (en) * 1992-07-10 1994-01-04 The United States Of America As Represented By The Department Of Health And Human Services Inhibition of diseases associated with amyloid formation
US5383988A (en) * 1992-09-10 1995-01-24 Paragon Trade Brands, Inc. Modular apparatus for fabricating an absorbent article
EP0599303A3 (en) * 1992-11-27 1998-07-29 Takeda Chemical Industries, Ltd. Peptide conjugate
US5401493A (en) * 1993-03-26 1995-03-28 Molecular Biosystems, Inc. Perfluoro-1H,-1H-neopentyl containing contrast agents and method to use same
US5643562A (en) * 1993-03-29 1997-07-01 Queen's University Of Kingston Method for treating amyloidosis
US5840294A (en) * 1993-03-29 1998-11-24 Queen's University At Kingston Method for treating amyloidosis
US5972328A (en) * 1993-03-29 1999-10-26 Queen's University At Kingston Method for treating amyloidosis
US5434137A (en) * 1993-05-10 1995-07-18 Black; Keith L. Method for selective opening of abnormal brain tissue capillaries
US5488145A (en) * 1993-12-23 1996-01-30 Oklahoma Medical Research Foundation 2,4-disulfonyl phenyl butyl nitrone, its salts, and their use as pharmaceutical free radical traps
US5466683A (en) * 1994-08-25 1995-11-14 Teva Pharmaceutical Industries Ltd. Water-soluble analogs of carbamazepine
US5660815A (en) * 1995-04-28 1997-08-26 Molecular Biosystems, Inc. Water soluble fluorinated fatty acid sulfonate derivatives useful as magnetic resonance imaging agents
US6015555A (en) * 1995-05-19 2000-01-18 Alkermes, Inc. Transferrin receptor specific antibody-neuropharmaceutical or diagnostic agent conjugates
US5858326A (en) * 1995-06-06 1999-01-12 Neurochem, Inc. Methods of increasing amyloid deposition
AU703540B2 (en) * 1996-03-26 1999-03-25 Meddiss, Incorporated Methods for inducing analgesia or anesthesia and treating or preventing ischemic injury of tissues in general
US5989592A (en) * 1996-10-03 1999-11-23 Coastside Bio Resources Inhibition of complement pathway by sea cucumber fractions
US5869469A (en) * 1997-08-18 1999-02-09 Queen's University At Kingston Phosphonocarboxylate compounds for treating amyloidosis
ES2200366T3 (es) * 1997-08-28 2004-03-01 University Of Washington Composiciones de sacaridos para el tratamiento de la enfermedad de alzheimer y otras amiloidoisis.
US5952389A (en) * 1998-01-13 1999-09-14 Synchroneuron Methods of treating tardive dyskinesia and other movement disorders
US6294583B1 (en) * 1998-01-13 2001-09-25 Synchroneuron, Llc Methods of treating tardive dyskinesia and other movement disorders
US6310073B1 (en) * 1998-07-28 2001-10-30 Queen's University At Kingston Methods and compositions to treat glycosaminoglycan-associated molecular interactions
DE60042896D1 (de) * 1999-04-28 2009-10-15 Bellus Health Int Ltd Zusammensetzungen und verfahren zur behandlung von amyloidosis mit sulphonatderivaten
US6562836B1 (en) * 1999-05-24 2003-05-13 Queen's University Of Kingston Methods and compounds for inhibiting amyloid deposits
US6376557B1 (en) * 2000-03-16 2002-04-23 Chanda Bhuwalka Zaveri Methods for treating alopecia
US20020115717A1 (en) * 2000-07-25 2002-08-22 Francine Gervais Amyloid targeting imaging agents and uses thereof
US7311893B2 (en) * 2000-07-25 2007-12-25 Neurochem (International) Limited Amyloid targeting imaging agents and uses thereof
JP2002214740A (ja) * 2001-01-22 2002-07-31 Konica Corp ハロゲン化銀カラー写真感光材料
AR033779A1 (es) * 2001-06-08 2004-01-07 Astrazeneca Ab Compuestos utiles en la enfermedad de reflujo
BR0215076A (pt) * 2001-12-19 2004-11-09 Clariant Finance Bvi Ltd Uso de uma matéria corante para imprimir materias de gravação
JP2004157370A (ja) * 2002-11-07 2004-06-03 Konica Minolta Holdings Inc ドライイメージング材料
WO2004058239A1 (en) * 2002-12-24 2004-07-15 Neurochem (International) Limited Therapeutic formulations for the treatment of beta-amyloid related diseases
WO2005000406A2 (en) * 2003-06-23 2005-01-06 Neurochem (International) Limited Treatment of amyloid- and epileptogenesis-associated diseases

Also Published As

Publication number Publication date
IL183079A0 (en) 2007-09-20
CA2586111A1 (en) 2006-06-08
US20060183800A1 (en) 2006-08-17
EP1828111A2 (en) 2007-09-05
JP2008519822A (ja) 2008-06-12
WO2006059252A3 (en) 2006-08-17
AU2005310986A1 (en) 2006-06-08
MX2007005507A (es) 2008-03-13
WO2006059252A2 (en) 2006-06-08

Similar Documents

Publication Publication Date Title
BRPI0517790A (pt) métodos e composições fluoradas para tratar doenças relacionadas à amilóide
CY1118660T1 (el) Συνθεσεις και μεθοδοι για την θεραπεια διαταραχων ματιων
DK1945622T3 (da) Isotopisk-mærkede benzofuranforbindelser som billeddannelsesmidler til amyloidogene proteiner
CY1121872T1 (el) Αξιολογηση, δοκιμασιες και θεραπεια των pkal-μεσολαβουμενων διαταραχων
BRPI0411743A (pt) método e composições para tratar doenças relacionadas a amilóides
WO2013022953A3 (en) Biomarker for alzheimer's disease and/or mild cognitively impairment, and use thereof
ES2422735T3 (es) Procedimiento para la predicción de un riesgo de reacciones adversas a medicamentos mediante la determinación de HLA-B 1502
ES2572372T3 (es) Método de diagnóstico de enfermedades neurodegenerativas basado en la medición de los niveles o de la actividad de SIRT1
WO2006059245A3 (en) Compounds for the treatment of cns and amyloid associated diseases
CY1118566T1 (el) Διαγνωση με χρηση ιντερφερονης τυπου 1
DK1831699T3 (da) Bestemmelse af neutrofil gelatine-associeret lipocalin (NGAL) som en diagnostisk markør for nyresygdomme
BRPI0507442A (pt) métodos de diagnóstico e tratamento de pré-eclampsia ou eclampsia
ECSP099238A (es) Amidas sustituidas, método de elaboración y método de uso de las mismas
ECSP099239A (es) Determinadas amidas sustituidas, método de elaboración y método de uso de las mismas
WO2006081521A3 (en) Methods for diagnosis and intervention of hepatic disorders
WO2006020269A3 (en) Biomarkers of neurodegenerative disease
NO20072035L (no) Memantin for behandling av adferdsforstyrrelser hos barn
WO2006134390A3 (en) Method for diagnosing neurodegenerative disease
BRPI0607507A2 (pt) método in vitro para a identificação de compostos para tratamento do cáncer
CY1119513T1 (el) Μεθοδοι και συνθεσεις για την διαγνωση και την θεραπευτικη αγωγη δευτερογενους αυτοανοσης νοσου της πολλαπλης σκληρυνσης
BRPI0512500A (pt) tratamento ou condições envolvendo desmielinação
WO2007030928A3 (en) Method for the diagnosis of colorectal cancer and ovarian cancer by the measurement of vitamin e-related metabolites
DK1915620T3 (da) Diagnose, behandling og prævention af vaskulære sygdomme ved hjælp af IL-1alpha-autoantistoffer
EP1953549A4 (en) ASBESTAN PROCEDURE, ASBESTAN DETERGENT, ASBESTAT PROTECTION KIT, AND METHOD FOR SEARCHING FOR CANDIDATES FOR A MEDICAMENT TO PREVENT OR TREAT ANY DISEASE OR CLAIMED ASBEST DISEASE
FI20031753A (fi) Parannettu mittausjärjestely röntgenfluoresenssianalyysiä varten

Legal Events

Date Code Title Description
B25D Requested change of name of applicant approved

Owner name: BELLUS HEALTH (INTERNATIONAL) LIMITED (CH)

Free format text: ALTERADO DE: NEUROCHEM (INTERNATIONAL) LIMITED

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 5A E 6A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2160 DE 29/05/2012.